Cellmid antibodies reduced kidney damage in mice
24 January, 2013 by Dylan Bushell-EmblingCellmid’s (ASX:CDY) anti-midkine antibodies were able to reduce kidney damage and preserve function in an animal model of diabetic nephropathy.
Uscom protocol slashed sepsis deaths: study
23 January, 2013 by Dylan Bushell-EmblingA Bathurst hospital reduced sepsis-related deaths by 94% by adopting a treatment protocol involving the use of Uscom (ASX:UCM) diagnostics tech, according to a new study.
Allied Healthcare closes $4.6m capital raising
23 January, 2013 by Dylan Bushell-EmblingAllied Healthcare (ASX:AHZ) will put the $4.6m raised in a placement and SPP towards launching its CardioCel heart patch as well as phase I trials of its DNA vaccine against herpes.
Abraxane extends life in advanced pancreatic cancer patients
23 January, 2013 by Tim DeanA phase III trial has shown Celgene’s Abraxane, distributed here by Specialised Therapeutics, has a significant impact on survival in patients with advanced pancreatic cancer.
Universal Biosensors expecting to launch new diagnostic in 2013
22 January, 2013 by Tim DeanUniversal Biosensors (ASX:UBI), in partnership with Siemens, expects to see its blood coagulation product hit the shelves this year, further boosting revenues for the company.
AusBiotech to host inaugural Australia China Life Science Summit
22 January, 2013 by AusBiotechAusBiotech will hold the inaugural Australia China Life Science Summit to share knowledge and gain expert views from others who have successfully created linkages and developed partnerships in the region.
Another European regulatory milestone for pSivida's Iluvien
18 January, 2013 by Tim DeanSpain's regulator has awarded marketing approval to pSivida's (ASX:PVA) Iluvien, leaving just Italy yet to give the treatment the tick ahead of a launch early this year.
ANZTPA discussion paper released for comment
17 January, 2013 by AusBiotechA discussion paper concerning the harmonisation of Australian and New Zealand therapeutic goods regulation is now open for comment.
Phosphagenics plans pain patch trial in Feb
16 January, 2013 by Dylan Bushell-EmblingPhosphagenics (ASX:POH) will launch a phase I trial of an oxymorphone pain patch in early February, less than six months after starting development on the product.
Bionomics boon from R&D Tax Incentive
15 January, 2013 by Dylan Bushell-EmblingBionomics (ASX:BNO) expects a larger-than-expected $4.2 million R&D tax incentive rebate for FY12, and will be now able to claim foreign expenditures under the program.
Australian bid wins international agricultural biotechnology conference
15 January, 2013 by AusBiotechAustralia has won the bid to host the 2015 Agricultural Biotechnology International Conference (ABIC), the world’s leading forum for the promotion of innovation in agricultural bioscience.
Bluechiip secures North America distribution deal
14 January, 2013 by Dylan Bushell-EmblingBluechiip (ASX:BCT) has signed a deal covering distribution of its temperature-resistant tracking chips in the North American sample storage market.
Patrys multiple myeloma trial progresses
14 January, 2013 by Dylan Bushell-EmblingPatrys (ASX:PAB) has started recruiting for a second group of three patients for its multiple myeloma trial, which will receive an escalated dose of antibody treatment PAB-SM6.
Productivity Commission releases draft report on compulsory licensing of patents
10 January, 2013 by AusBiotechAfter reviewing the compulsory licensing provisions in the patents system, the Productivity Commission has released a draft report, which is now open for comment until 8 February 2013.
Allied Healthcare explores new tissue engineering applications
10 January, 2013 by Tim DeanA study has shown Allied Healthcare’s (ASX:AHZ) tissue engineering technology has potential applications in hernia repair and pelvic floor reconstruction.
